bio-techne
TOCRIS

Print Date: Jul 2nd 2026

Certificate of Analysis

www.tocris.com

Product Name: **SNDX-5613** **Catalog No.: 8907** **Batch No.: 1**

CAS Number: 2169919-21-3

IUPAC Name: *N*-Ethyl-2-[[4-[7-[[*trans*-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-*N*-(1-methylethyl)benzamide

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{32}H_{47}FN_6O_4S$

Batch Molecular Weight: 630.82

Physical Appearance: White solid

Solubility: DMSO to 50 mM
ethanol to 20 mM

Storage: Store at -20°C

Batch Molecular Structure:



2. ANALYTICAL DATA

HPLC: Shows 97.8% purity

^{1}H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	60.93	7.51	13.32
Found	61.03	7.55	13.26

bio-techne.com
info@bio-techne.com
techsupport@bio-techne.com

North America
Tel: (800) 343 7475

China
info.cn@bio-techne.com
Tel: +86 (21) 52380373

Europe Middle East Africa
Tel: +44 (0)1235 529449

Rest of World
www.tocris.com/distributors
Tel:+1 612 379 2956

Product Name: **SNDX-5613** **Catalog No.: 8907** **Batch No.: 1**

CAS Number: 2169919-21-3

IUPAC Name: *N*-Ethyl-2-[[4-[7-[[*trans*-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-*N*-(1-methylethyl)benzamide

Description:

SNDX-5613 is a potent inhibitor of menin-MLL1 protein-protein interaction (Ki = 0.149 nM; IC50 = 10-20 nM). Induces promising antileukaemic activity leading to deep and sustained remission in patients with highly refractory acute leukaemia with KMT2Ar or NPM1 mutation.

Physical and Chemical Properties:

Batch Molecular Formula: $C_{32}H_{47}FN_6O_4S$

Batch Molecular Weight: 630.82

Physical Appearance: White solid

Minimum Purity: ≥98%

Batch Molecular Structure:



Storage: Store at -20°C

Solubility & Usage Info:

DMSO to 50 mM
ethanol to 20 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. *Unless contradicted by product-specific protocols or instructions, our standard recommendations apply:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Fiskus *et al* (2023) Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. ***13***. PMID: 37055414.

Issa *et al* (2023) The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature ***615*** 920. PMID: 36922593.

Perner *et al* (2023) MEN1 mutations mediate clinical resistance to menin inhibition. ***615*** 913. PMID: 36922589.